SynAct Pharma AB (SYNACT) Stock Overview

SynAct Pharma AB, a clinical stage biotechnology company, engages in the research and development of medicines for the treatment of inflammatory diseases. It is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. The company also develops TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failures in complicated surgery; and various drug programs to treat auto-immune diseases. The company was founded in 2012 and is headquartered in Lund, Sweden.